$RDY News

Dr. Reddy's Laboratories Limited Announces USFDA Classifies FTO-SEZ Process Unit-02 Inspection as Voluntary Action Indicated

RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall

Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript

Dr. Reddy's Laboratories Limited Reports Q2 FY 2027 Financial Results

Dr. Reddy's Laboratories Limited Appoints Akhil Ravi as Head API and Services Effective November 13, 2026

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories Limited Reports Revenues of Rs. 86,708 Million for the Quarter Ended September 30, 2026

Dr Reddy's Laboratories Q2 2027 Earnings Call Transcript

Dr Reddy's Laboratories Q2 EPS $0.12 Misses $0.16 Estimate, Sales $905.000M Miss $980.650M Estimate

Dr Reddy's Says FDA Completed Pre-Approval Inspection At The FTO-11 Manufacturing Facility In Pydibhimavaram

Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450

Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript

Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement Termination

Dr. Reddy's Laboratories Limited - Depositary Receipt (RDY) Price Target Decreased by 12.65% to 12.93

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Dr. Reddy’s Laboratories Announces U.S. FDA Completes Inspection at Srikakulam Unit, Issues Form 483

Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

Dr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call Transcript

Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat